Artificial intelligence and related technologies enabled nanomedicine for advanced cancer treatment

The regulatory approval of injectable liposomal preparations such as Doxil® (AIDS-related Kaposi’s sarcoma and cancer of the ovaries), Myocet™ (metastatic breast cancer), DaunoXome® (advanced HIV-associated Kaposi’s sarcoma) and nanoparticle formulations like Abraxane® (metastatic breast cancer, adv...

Full description

Saved in:
Bibliographic Details
Published in:Nanomedicine (London, England) England), 2020-02, Vol.15 (5), p.433-435
Main Authors: Wilson, Barnabas, Km, Geetha
Format: Article
Language:English
Subjects:
Alzheimer's disease
Artificial intelligence
Brain research
Breast cancer
cancer
Cancer therapies
Clinical trials
Drug dosages
Drug synergism
FDA approval
feedback system control
Lung cancer
Medical research
Medicine
Metastasis
Multiple myeloma
nanomedicine
Nanoparticles
Nanotechnology
Oncology
Optimization
Ovarian cancer
Pancreatic cancer
Patients
Prostate
Quantum dots
Regulatory approval
Sarcoma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The regulatory approval of injectable liposomal preparations such as Doxil® (AIDS-related Kaposi’s sarcoma and cancer of the ovaries), Myocet™ (metastatic breast cancer), DaunoXome® (advanced HIV-associated Kaposi’s sarcoma) and nanoparticle formulations like Abraxane® (metastatic breast cancer, advanced non-small-cell lung cancer, metastatic pancreatic cancer) by the US FDA shows the transformation of nanomedicine-based products from the laboratory to the bedside. Recently, injectable liposomal irinotecan (Onivyde™) for treating metastatic pancreatic cancer and injectable liposomal cytarabine and daunorubicin (Vyxeos®) for acute myeloid leukemia has also been approved by the FDA and others are in various phases of clinical trials. [...]a combination of AI and nanomedicine can overcome the challenges and improve the efficacy of cancer therapy (10). [...]it is important to address the regulatory concerns.
ISSN:1743-5889
1748-6963
DOI:10.2217/nnm-2019-0366